[go: up one dir, main page]

HUE056006T2 - Kombináció Parkinson-kór kezelésére - Google Patents

Kombináció Parkinson-kór kezelésére

Info

Publication number
HUE056006T2
HUE056006T2 HUE14718177A HUE14718177A HUE056006T2 HU E056006 T2 HUE056006 T2 HU E056006T2 HU E14718177 A HUE14718177 A HU E14718177A HU E14718177 A HUE14718177 A HU E14718177A HU E056006 T2 HUE056006 T2 HU E056006T2
Authority
HU
Hungary
Prior art keywords
parkinson
disease
treatment
combination
Prior art date
Application number
HUE14718177A
Other languages
English (en)
Inventor
Oron Yacoby-Zeevi
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50513395&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE056006(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of HUE056006T2 publication Critical patent/HUE056006T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE14718177A 2013-03-13 2014-03-13 Kombináció Parkinson-kór kezelésére HUE056006T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361779357P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
HUE056006T2 true HUE056006T2 (hu) 2022-01-28

Family

ID=50513395

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14718177A HUE056006T2 (hu) 2013-03-13 2014-03-13 Kombináció Parkinson-kór kezelésére

Country Status (21)

Country Link
US (3) US20160022573A1 (hu)
EP (2) EP3892266A1 (hu)
JP (2) JP6472391B2 (hu)
KR (1) KR102209353B1 (hu)
CN (2) CN110935026A (hu)
AU (1) AU2014229127B2 (hu)
BR (1) BR112015022390A8 (hu)
CA (1) CA2904838C (hu)
CL (1) CL2015002641A1 (hu)
DK (1) DK2968218T3 (hu)
ES (1) ES2889626T3 (hu)
HR (1) HRP20211442T1 (hu)
HU (1) HUE056006T2 (hu)
IL (1) IL266648B (hu)
MX (1) MX365206B (hu)
PL (1) PL2968218T3 (hu)
PT (1) PT2968218T (hu)
RU (2) RU2677278C2 (hu)
SG (2) SG11201507538UA (hu)
WO (1) WO2014141261A1 (hu)
ZA (1) ZA201507621B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193243B2 (en) 2009-05-19 2012-06-05 Neuroderm, Ltd. Continuous administration of dopa decarboxylase inhibitors and compositions for same
LT2640370T (lt) 2010-11-15 2018-09-10 Neuroderm Ltd Kompozicijos, skirtos aktyvių agentų įvedimui po oda
PL3326615T3 (pl) 2010-11-15 2020-07-27 Neuroderm Ltd Ciągłe podawanie L-dopy, inhibitorów dekarboksylazy dopy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
MX2016011837A (es) * 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
PT3188725T (pt) 2014-09-04 2021-01-27 Lobsor Pharmaceuticals Ab Composições farmacêuticas compreendendo levodopa, um inibidor de descarboxílase de dopamina e um inibidor de comt, e método de administração destes
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
AU2018280745B2 (en) * 2017-06-05 2023-03-09 Dizlin Pharmaceuticals Ab Levodopa infusion solution
WO2019097120A1 (en) * 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
WO2019147934A1 (en) * 2018-01-29 2019-08-01 Sackner Bernstein Jonathan Methods for dopamine modulation in human neurologic diseases
WO2019191353A1 (en) * 2018-03-29 2019-10-03 Riverside Pharmaceuticals Corporation Levodopa fractionated dose composition and use
JP2022507528A (ja) 2018-11-15 2022-01-18 アッヴィ・インコーポレイテッド 皮下投与のための医薬製剤
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
WO2023282900A1 (en) * 2021-07-08 2023-01-12 Morehouse School Of Medicine Method and system of diagnosing and treating neurodegenerative disease and seizures
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
JP5336181B2 (ja) * 2005-06-08 2013-11-06 オリオン コーポレーション 経口投薬形態
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
US8193243B2 (en) * 2009-05-19 2012-06-05 Neuroderm, Ltd. Continuous administration of dopa decarboxylase inhibitors and compositions for same
PL3326615T3 (pl) * 2010-11-15 2020-07-27 Neuroderm Ltd Ciągłe podawanie L-dopy, inhibitorów dekarboksylazy dopy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji

Also Published As

Publication number Publication date
MX2015012561A (es) 2016-06-28
ZA201507621B (en) 2019-04-24
BR112015022390A2 (pt) 2017-07-18
DK2968218T3 (da) 2021-09-20
BR112015022390A8 (pt) 2019-11-26
JP6625773B2 (ja) 2019-12-25
US20210093560A1 (en) 2021-04-01
SG10201911731YA (en) 2020-02-27
CA2904838A1 (en) 2014-09-18
RU2018144700A (ru) 2019-02-18
PT2968218T (pt) 2021-09-24
AU2014229127B2 (en) 2018-04-05
SG11201507538UA (en) 2015-10-29
IL266648A (en) 2019-07-31
ES2889626T3 (es) 2022-01-12
JP2019070041A (ja) 2019-05-09
RU2015143112A (ru) 2017-04-20
CA2904838C (en) 2021-03-16
CN105209029A (zh) 2015-12-30
KR102209353B1 (ko) 2021-01-29
US20230047847A1 (en) 2023-02-16
MX365206B (es) 2019-05-27
PL2968218T3 (pl) 2022-01-10
EP2968218A1 (en) 2016-01-20
AU2014229127A1 (en) 2015-11-05
US20160022573A1 (en) 2016-01-28
RU2677278C2 (ru) 2019-01-16
KR20150131230A (ko) 2015-11-24
WO2014141261A1 (en) 2014-09-18
JP2016512230A (ja) 2016-04-25
EP3892266A1 (en) 2021-10-13
CN110935026A (zh) 2020-03-31
JP6472391B2 (ja) 2019-02-20
IL266648B (en) 2020-08-31
CL2015002641A1 (es) 2016-03-18
EP2968218B1 (en) 2021-07-07
HRP20211442T1 (hr) 2022-02-04

Similar Documents

Publication Publication Date Title
IL280530A (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
IL266648B (en) A method for treating Parkinson's disease
SG11202012656WA (en) Heterocyclic compounds useful in the treatment of disease
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
IL243976A0 (en) kdm1a inhibitors for disease treatment
EP2964084A4 (en) SHAPE FACTORS FOR MULTIMODAL PHYSIOLOGICAL ASSESSMENT OF BRAIN HEALTH
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
HK1219653A1 (zh) 治療線粒體疾病的方法
IL263188B (en) Treatment for Parkinson's disease
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
IL243637B (en) PPAR-sparing compounds for the treatment of metabolic diseases
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
ZA201807944B (en) Treatment for parkinson's disease
IL241482A0 (en) A method for treating Parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
GB201504144D0 (en) Treatment of Parkinson's disease
GB201310101D0 (en) Treatment of freidreich's ataxia
GB201306413D0 (en) The local treatment of ophthalmic diseases
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS